Tags

Type your tag names separated by a space and hit enter

Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial.
J Perinat Med. 2014 Mar; 42(2):197-206.JP

Abstract

OBJECTIVE

To compare the effects of oral ferrous bisglycinate 25 mg iron/day vs. ferrous sulfate 50 mg iron/day in the prevention of iron deficiency (ID) and iron deficiency anemia (IDA) in pregnant women.

DESIGN

Randomized, double-blind, intention-to-treat study.

SETTING

Antenatal care clinic.

SAMPLE

80 healthy ethnic Danish pregnant women.

METHODS

Women were allocated to ferrous bisglycinate 25 mg elemental iron (Aminojern®) (n=40) or ferrous sulfate 50 mg elemental iron (n=40) from 15 to 19 weeks of gestation to delivery. Hematological status (hemoglobin, red blood cell indices) and iron status (plasma iron, plasma transferrin, plasma transferrin saturation, plasma ferritin) were measured at 15-19 weeks (baseline), 27-28 weeks and 36-37 weeks of gestation.

MAIN OUTCOME MEASURES

Occurrence of ID (ferritin <15 μg/L) and IDA (ferritin <12 μg/L and hemoglobin <110 g/L).

RESULTS

At inclusion, there were no significant differences between the bisglycinate and sulfate group concerning hematological status and iron status. The frequencies of ID and IDA were low and not significantly different in the two iron groups. The frequency of gastrointestinal complaints was lower in the bisglycinate than in the sulfate group (P=0.001). Newborns weight was slightly higher in the bisglycinate vs. the sulfate group (3601±517 g vs. 3395±426 g, P=0.09).

CONCLUSIONS

In the prevention of ID and IDA, ferrous bisglycinate was not inferior to ferrous sulfate. Ferrous bisglycinate in a low dose of 25 mg iron/day appears to be adequate to prevent IDA in more than 95% of Danish women during pregnancy and postpartum.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24152889

Citation

Milman, Nils, et al. "Ferrous Bisglycinate 25 Mg Iron Is as Effective as Ferrous Sulfate 50 Mg Iron in the Prophylaxis of Iron Deficiency and Anemia During Pregnancy in a Randomized Trial." Journal of Perinatal Medicine, vol. 42, no. 2, 2014, pp. 197-206.
Milman N, Jønsson L, Dyre P, et al. Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. J Perinat Med. 2014;42(2):197-206.
Milman, N., Jønsson, L., Dyre, P., Pedersen, P. L., & Larsen, L. G. (2014). Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. Journal of Perinatal Medicine, 42(2), 197-206. https://doi.org/10.1515/jpm-2013-0153
Milman N, et al. Ferrous Bisglycinate 25 Mg Iron Is as Effective as Ferrous Sulfate 50 Mg Iron in the Prophylaxis of Iron Deficiency and Anemia During Pregnancy in a Randomized Trial. J Perinat Med. 2014;42(2):197-206. PubMed PMID: 24152889.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. AU - Milman,Nils, AU - Jønsson,Lisbeth, AU - Dyre,Pernille, AU - Pedersen,Palle Lyngsie, AU - Larsen,Lise Grupe, PY - 2013/06/25/received PY - 2013/09/08/accepted PY - 2013/10/25/entrez PY - 2013/10/25/pubmed PY - 2014/12/15/medline SP - 197 EP - 206 JF - Journal of perinatal medicine JO - J Perinat Med VL - 42 IS - 2 N2 - OBJECTIVE: To compare the effects of oral ferrous bisglycinate 25 mg iron/day vs. ferrous sulfate 50 mg iron/day in the prevention of iron deficiency (ID) and iron deficiency anemia (IDA) in pregnant women. DESIGN: Randomized, double-blind, intention-to-treat study. SETTING: Antenatal care clinic. SAMPLE: 80 healthy ethnic Danish pregnant women. METHODS: Women were allocated to ferrous bisglycinate 25 mg elemental iron (Aminojern®) (n=40) or ferrous sulfate 50 mg elemental iron (n=40) from 15 to 19 weeks of gestation to delivery. Hematological status (hemoglobin, red blood cell indices) and iron status (plasma iron, plasma transferrin, plasma transferrin saturation, plasma ferritin) were measured at 15-19 weeks (baseline), 27-28 weeks and 36-37 weeks of gestation. MAIN OUTCOME MEASURES: Occurrence of ID (ferritin <15 μg/L) and IDA (ferritin <12 μg/L and hemoglobin <110 g/L). RESULTS: At inclusion, there were no significant differences between the bisglycinate and sulfate group concerning hematological status and iron status. The frequencies of ID and IDA were low and not significantly different in the two iron groups. The frequency of gastrointestinal complaints was lower in the bisglycinate than in the sulfate group (P=0.001). Newborns weight was slightly higher in the bisglycinate vs. the sulfate group (3601±517 g vs. 3395±426 g, P=0.09). CONCLUSIONS: In the prevention of ID and IDA, ferrous bisglycinate was not inferior to ferrous sulfate. Ferrous bisglycinate in a low dose of 25 mg iron/day appears to be adequate to prevent IDA in more than 95% of Danish women during pregnancy and postpartum. SN - 1619-3997 UR - https://www.unboundmedicine.com/medline/citation/24152889/Ferrous_bisglycinate_25_mg_iron_is_as_effective_as_ferrous_sulfate_50_mg_iron_in_the_prophylaxis_of_iron_deficiency_and_anemia_during_pregnancy_in_a_randomized_trial_ L2 - https://www.degruyter.com/doi/10.1515/jpm-2013-0153 DB - PRIME DP - Unbound Medicine ER -